Umicore Precious Metals Chemistry
Umicore Precious Metals Chemistry offers a collaborative approach to research, development and commercial manufacturing of your complex organometallic chemistry and catalysis needs.
Umicore Precious Metals Chemistry is part of the Umicore group, a global materials technology company with locations around the world. With over 50 years experience in the platinum group metals chemistry and 20 years experience in organometallics, Umicore Precious Metals Chemistry is dedicated to continuous improvement and investing in sustainable technology.
Our focus is co-creating with our customers to innovate their process for next generation technologies. Collaborating and co-creating is the future of problem solving across many industries, including complex chemistry. At Umicore Precious Metals Chemistry, we offer an integrated long-term collaborative partnership approach to research, development and commercial manufacturing of complex chemistry needs for sustainable technologies.
Our deep understanding of industry regulations, and our experience in writing our own, enable our customers to benefit from the proud reputation we have earned in sustainable technologies, sourcing and ethical practice. Through working together, we can produce solutions to long-standing issues and create ground-breaking science to pioneer future products across many industries.
Contact Details:
Company name: Umicore Precious Metals Chemistry
Website: pmc.umicore.com
E-mail: chemistry@umicore.com
Stand/Booth number: CPhI Hall 6.0, Booth 60D53
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
